Dr. Fredrickson continued by noting that recombinant DNA 
techniques and the policies governing their use can serve as a case 
model for public and scientific participation in developing national 
and international science policy. He reminded the audience that the 
subject of this meeting is the proposed revision of existing Guide- 
lines and its purpose is to develop facts and opinions concerning the 
next stage of development of the Guidelines. 
Dr. Fredrickson concluded his introduction by describing the 
format of the meeting. The review of each relevant section would begin 
with a short presentation by a member of the Recombinant DNA Molecule 
Program Advisory Committee (RAC), followed by comments from invited 
witnesses and public witnesses respectively. Members of the Advisory 
Committee to the Director, NIH (DAC) would have the opportunity to 
question witnesses in a frank and open discussion of views. Towards 
the close of the meeting each member of the DAC would provide a brief 
oral summary and then follow at some future date with more detailed 
written comments. Dr. Fredrickson urged all interested participants 
to submit comments. 
Introduction to the Proposed Revised Guidelin es 
Dr. John Littlefield (RAC) briefly described the Introduction 
to the Guidelines. He noted that the term "recombinant DNA" had been 
redefined and that the members of the RAC believed the new definition 
to be a workable one. The definition will exclude certain types 
ii 
[ 188 ] 
